ALK and neoplasm: 收集所有患者的临床资料,包括年龄、性别、肿瘤原发灶-淋巴结-转移(tumor-node-metastasis, TNM)分期、胸部影像和支气管镜结果、病理类型、基因[包括表皮生长因子受体(epidermal growth factor receptor, EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)/ROS原癌基因1受体酪氨酸激酶(ROS proto-oncogene 1 receptor tyrosine kinase, ROS1)]突变以及总生存期。